0000000001240709

AUTHOR

Y. Kim

showing 11 related works from this author

Search for an Invisibly Decaying Z′ Boson at Belle II in e+e−→μ+μ−(e±μ∓) Plus Missing Energy Final States

2020

Theories beyond the standard model often predict the existence of an additional neutral boson, the Z′. Using data collected by the Belle II experiment during 2018 at the SuperKEKB collider, we perform the first searches for the invisible decay of a Z′ in the process e+e-→μ+μ-Z′ and of a lepton-flavor-violating Z′ in e+e-→e±μZ′. We do not find any excess of events and set 90% credibility level upper limits on the cross sections of these processes. We translate the former, in the framework of an Lμ-Lτ theory, into upper limits on the Z′ coupling constant at the level of 5×10-2-1 for MZ′≤6 GeV/c2.

PhysicsCoupling constantParticle physicsMissing energyPhysics beyond the Standard ModelGeneral Physics and Astronomy01 natural scienceslaw.inventionlaw0103 physical sciencesHigh Energy Physics::Experiment010306 general physicsColliderBosonPhysical Review Letters
researchProduct

Measurement of exclusive γγ→ℓ+ℓ− production in proton–proton collisions at s=7 TeV with the ATLAS detector

2015

This Letter reports a measurement of the exclusive gamma gamma -> l(+)l(-) (l = e, mu) cross-section in proton-proton collisions at a centre-of-mass energy of 7 TeV by the ATLAS experiment at the LHC, based on an integrated luminosity of 4.6 fb(-1). For the electron or muon pairs satisfying exclusive selection criteria, a fit to the dilepton acoplanarity distribution is used to extract the fiducial cross-sections. The cross-section in the electron channel is determined to be sigma(excl)(gamma gamma -> e+e-) = 0.428 +/- 0.035 (stat.) +/- 0.018 (syst.) pbfor a phase-space region with invariant mass of the electron pairs greater than 24GeV, in which both electrons have transverse momentum p(T)…

PhysicsNuclear and High Energy PhysicsParticle physicsLarge Hadron ColliderMuonProtonATLAS experimentAcoplanarityNuclear physicsmedicine.anatomical_structureAtlas (anatomy)PseudorapiditymedicineHigh Energy Physics::ExperimentInvariant massNuclear ExperimentPhysics Letters B
researchProduct

Precise Measurement of the D0 and D+ Lifetimes at Belle II

2021

We report a measurement of the D^{0} and D^{+} lifetimes using D^{0}→K^{-}π^{+} and D^{+}→K^{-}π^{+}π^{+} decays reconstructed in e^{+}e^{-}→cc[over ¯] data recorded by the Belle II experiment at the SuperKEKB asymmetric-energy e^{+}e^{-} collider. The data, collected at center-of-mass energies at or near the ϒ(4S) resonance, correspond to an integrated luminosity of 72  fb^{-1}. The results, τ(D^{0})=410.5±1.1(stat)±0.8(syst)  fs and τ(D^{+})=1030.4±4.7(stat)±3.1(syst)  fs, are the most precise to date and are consistent with previous determinations.

PhysicsParticle physics010308 nuclear & particles physicslaw0103 physical sciencesGeneral Physics and AstronomyResonance010306 general physicsCollider01 natural scienceslaw.inventionLuminosityPhysical Review Letters
researchProduct

Towards a test of the weak equivalence principle of gravity using anti-hydrogen at CERN

2016

International audience; The aim of the GBAR (Gravitational Behavior of Antimatter at Rest) experiment is to measure the free fall acceleration of an antihydrogen atom, in the terrestrial gravitational field at CERN and therefore test the Weak Equivalence Principle with antimatter. The aim is to measure the local gravity with a 1% uncertainty which can be reduced to few parts of 10-3.

Free fallGravity (chemistry)Particle physicsPhysics::General PhysicsAntimatterCERN LabGravityacceleration measurementterrestrial gravitational fieldfree fall acceleration01 natural sciencesantihydrogen: accelerationweak equivalence principle010305 fluids & plasmasparticle trapsAtomic measurementsGravitationGeneral Relativity and Quantum Cosmologyhydrogen: ionGravitational fieldLaser transitionsAtom (measure theory)0103 physical sciencesPhysics::Atomic and Molecular Clusters[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsAntihydrogenantihydrogen atomPhysicsIonsatomProductionEquivalence principle (geometric)laserequivalence principleAntimatter[PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc]talk: Ottawa 2016/07/10gravitation: localhydrogen ionsCoolingGravitation
researchProduct

AKI - human studies

2013

03 medical and health sciencesTransplantationmedicine.medical_specialty0302 clinical medicineHuman studiesNephrologybusiness.industry030232 urology & nephrologyMedicine030204 cardiovascular system & hematologybusinessIntensive care medicineNephrology Dialysis Transplantation
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct

LAB-STEM CELLS

2012

AbstractsCancer ResearchOncologybusiness.industryMedicineNeurology (clinical)Stem cellbusinessCell biologyNeuro-Oncology
researchProduct

Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a…

2020

Background Accurate and up-to-date assessment of demographic metrics is crucial for understanding a wide range of social, economic, and public health issues that affect populations worldwide. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 produced updated and comprehensive demographic assessments of the key indicators of fertility, mortality, migration, and population for 204 countries and territories and selected subnational locations from 1950 to 2019. Methods 8078 country-years of vital registration and sample registration data, 938 surveys, 349 censuses, and 238 other sources were identified and used to estimate age-specific fertility. Spatiotemporal Gaussian…

Malevery elderlyDemographic transitionHALE030204 cardiovascular system & hematologypreschool childGlobal Burden of DiseaseCarga Global de Enfermedades0302 clinical medicinenewbornRisk FactorsSurveys and Questionnairesand Risk Factors Study80 and over030212 general & internal medicineBirth RateChildMigration11 Medical and Health SciencesAged 80 and overeducation.field_of_studyInjuriesGeographyMortality rate1. No povertyDEATHCensusesGeneral MedicineSDG 10 - Reduced InequalitiesMiddle AgedDemographic analysis3142 Public health care science environmental and occupational health3. Good healthdemographic analysisEstilo de Vida SaludableGeographyrisk factorChild Preschool/dk/atira/pure/sustainabledevelopmentgoals/reduced_inequalitiesDemography/statistics & numerical dataGlobal Burden of Diseases Injuries Risk Factors Fertility Mortality Migration Population/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingepidemiologyFemaleA990 Medicine and Dentistry not elsewhere classifiedCHILD-MORTALITYLive BirthGlobal Health MetricsTRANSITIONdemographics ; GBD ; fertility ; mortality ; haleAdultAdolescentTotal fertility ratePopulationPopulation.Global Burden of Diseases Injuries and Risk Factors StudyBirth rate03 medical and health sciencesYoung AdultLife ExpectancySDG 3 - Good Health and Well-beingGeneral & Internal MedicineSYSTEMATIC ANALYSISDemografíaHumansGlobal Burden of Disease StudyhumanMortalityeducationPreschoolAgedDemographySpatial AnalysisquestionnaireInfant NewbornKlinisk medicinHIVInfantGlobal Burden of Diseasessex-specific fertilityMortality rateLive Birth/epidemiology//purl.org/pe-repo/ocde/ford#3.02.00 [https].Global Burden of DiseasesMODELFertilidadFertilityDemographic changeLife expectancyNAglobal disease burdenClinical Medicinepopulation researchDemographyThe Lancet
researchProduct

Five insights from the Global Burden of Disease Study 2019

2020

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a rules-based synthesis of the available evidence on levels and trends in health outcomes, a diverse set of risk factors, and health system responses. GBD 2019 covered 204 countries and territories, as well as first administrative level disaggregations for 22 countries, from 1990 to 2019. Because GBD is highly standardised and comprehensive, spanning both fatal and non-fatal outcomes, and uses a mutually exclusive and collectively exhaustive list of hierarchical disease and injury causes, the study provides a powerful basis for detailed and broad insights on global health trends and emerging challenges. GBD …

health care deliveryMaleHumans -- MalatiesOutcome Assessmentglobal healthDiseaseReviewinsights030204 cardiovascular system & hematologySocioeconomic FactorgeographyGlobal Burden of DiseaseNoncommunicable Diseasedisease burdenCarga Global de Enfermedades0302 clinical medicineRisk FactorsOutcome Assessment Health CareHealth careGlobal healthDelivery of health carehealth outcomesmiddle income countrybirth rate030212 general & internal medicineBirth Ratehealth outcomes health system responses economic developmentFactores de Riesgopublic healthhealth care costGeneral MedicineRisk factor (computing)humanities3. Good healthfemalepriority journalrisk factorhealth system responsesepidemiologyTERRITORIESpoliticsCLINICAL-TRIALSmedicine.medical_specialtyBirth Rate; Delivery of Health Care; Global Burden of Disease; Noncommunicable Diseases; Outcome Assessment Health Care; Risk Factors; Socioeconomic Factors; Wounds and Injuries; epidemiologyinjury2019195 COUNTRIESArticleGlobal Burden of Diseases health outcomes risk factors health system responsesHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]03 medical and health sciencessocioeconomicsmedicineSYSTEMATIC ANALYSISHumansGlobal Burden of Disease StudyhumanEpidemiologiaNoncommunicable DiseasesDisease burdenActuarial sciencehigh income countrybusiness.industryRisk FactorWounds and InjuriePublic healthagingHealth careeconomicsNon-communicable diseasemedicine.diseaseSalut públicaeconomic developmentEnfermedadesnon communicable disease//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health CareRisk factorsSocioeconomic Factorspopulation growthLife expectancylife expectancyWounds and InjuriesNAPrestación de Atención de Saludglobal disease burdenbusinessDelivery of Health Carelow income country
researchProduct

The ALICE Collaboration

2009

The production of mesons containing strange quarks (KS, φ) and both singly and doubly strange baryons ( , , and − + +) are measured at mid-rapidity in pp collisions at √ s = 0.9 TeV with the ALICE experiment at the LHC. The results are obtained from the analysis of about 250 k minimum bias events recorded in 2009. Measurements of yields (dN/dy) and transverse momentum spectra at mid-rapidity for inelastic pp collisions are presented. For mesons, we report yields (〈dN/dy〉) of 0.184 ± 0.002(stat.) ± 0.006(syst.) for KS and 0.021 ± 0.004(stat.) ± 0.003(syst.) for φ. For baryons, we find 〈dN/dy〉 = 0.048 ± 0.001(stat.) ± 0.004(syst.) for , 0.047 ± 0.002(stat.) ± 0.005(syst.) for and 0.0101 ± 0.0…

PhysicsStrange quarkNuclear and High Energy PhysicsLarge Hadron ColliderMeson010308 nuclear & particles physics7. Clean energy01 natural sciencesSpectral lineVisual artsNuclear physicsBaryonMinimum biasTransverse momentum0103 physical sciencesHigh Energy Physics::ExperimentAstrophysics::Earth and Planetary AstrophysicsALICE (propellant)Nuclear Experiment010306 general physics
researchProduct

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.201…

2016

non presente

Molecular Biology; Cell BiologyCell BiologySettore BIO/06 - Anatomia Comparata E CitologiaMolecular Biology
researchProduct